Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surfactant replacement therapy

H L Halliday1

  • 1Queen's University of Belfast, Northern Ireland.

Pediatric Pulmonology. Supplement
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Surfactant replacement therapy significantly reduces neonatal death and lung air leaks in premature infants. Early or preventative treatment, especially with natural surfactants, offers the best outcomes, complementing prenatal steroids.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum versus Retraction.

Neonatology·2018
Same author

[European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2014
Same author

Maternité Prize of the European Association of Perinatal Medicine. Laudatio for Christian P. Speer, MD, FRCPE Professor of Pediatrics.

Zeitschrift fur Geburtshilfe und Neonatologie·2014
Same author

Mikko Hallman--a major translator of basic science into neonatal medicine.

Zeitschrift fur Geburtshilfe und Neonatologie·2012
Same author

Intra-uterine growth restriction and increased risk of hypertension in adult life: a follow-up study of 50-year-olds.

Public health·2012
Same author

[European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2011
Same journal

Outcome after Liver Transplantation for Cystic Fibrosis.

Pediatric pulmonology. Supplement·2011
Same journal

Abstracts of the 23rd Annual North American Cystic Fibrosis Conference, Minneapolis, Minnesota, USA, October 15-17, 2009.

Pediatric pulmonology. Supplement·2009
Same journal

Abstracts of the 21st Annual North American Cystic Fibrosis Conference, October 23-25, 2008, Orlando, Florida, USA.

Pediatric pulmonology. Supplement·2008
Same journal

Abstracts of the 21st Annual North American Cystic Fibrosis Conference, October 3-6, 2007, Anaheim, California, USA.

Pediatric pulmonology. Supplement·2007
Same journal

Abstracts of the 20th Annual North American Cystic Fibrosis Conference, November 2-5, 2006, Denver, Colorado, USA.

Pediatric pulmonology. Supplement·2006
Same journal

Abstracts of the 19th Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 20-23, 2005.

Pediatric pulmonology. Supplement·2005
See all related articles

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Biochemistry

Background:

  • Respiratory Distress Syndrome (RDS) is a major cause of neonatal mortality.
  • Surfactant replacement therapy (SRT) has been a focus of research for RDS treatment and prevention.
  • Understanding surfactant types and optimal treatment timing is crucial for improving infant outcomes.

Purpose of the Study:

  • To evaluate the effectiveness of surfactant replacement therapy in treating and preventing RDS.
  • To compare the efficacy of natural versus synthetic surfactants.
  • To determine the optimal timing for surfactant administration in preterm infants.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Comparison of outcomes between different types of surfactants (natural vs. synthetic).

Related Experiment Videos

  • Analysis of treatment timing (prophylaxis, early, late) and its impact on neonatal outcomes.

    • Main Results:

    • SRT reduces neonatal mortality by approximately 40% and pulmonary air leaks by 35-70%.
    • Prophylactic or very early SRT is superior to later treatment, particularly for infants born before 28 weeks gestation.
    • Natural surfactants may offer faster onset and better long-term benefits than synthetic ones, though further trials are needed.

    Conclusions:

    • Surfactant replacement therapy is a highly effective intervention for RDS.
    • Optimal timing and type of surfactant are critical for maximizing benefits in preterm neonates.
    • SRT and prenatal steroid therapy are synergistic and should be used in conjunction for enhanced fetal lung maturity and survival.